- Home
- Products
Vanflyta (Quizartinib)
Vanflyta (Quizartinib)
- Medicine Name: VANFLYTA
- Generic Name: Quizartinib Dihydrochloride
- Dosage Form & Strength: Tablets – 17.7 mg and 26.5 mg
- Manufactured By: Daiichi Sankyo, Inc.
VANFLYTA (Quizartinib) is a FLT3 inhibitor used in combination with standard chemotherapy (cytarabine and anthracycline) and as maintenance monotherapy for the treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML) in adults.
Treatment Phases & Dosage:
- Induction: 35.4 mg orally once daily on Days 8–21 of the “7+3” chemotherapy regimen, and optionally repeated in a second induction cycle.
- Consolidation: 35.4 mg orally once daily on Days 6–19 of high-dose cytarabine for up to 4 cycles.
- Maintenance: 26.5 mg orally once daily on Days 1–14, then 53 mg once daily thereafter, for up to thirty-six 28-day cycles.
Tablets should be taken at the same time daily, with or without food. Do not crush, chew, or split the tablets. If a dose is missed, take it as soon as possible on the same day. Do not double doses.
QT Prolongation & Cardiac Monitoring: Monitor ECG and electrolytes during treatment.
Myelosuppression Risk: May cause neutropenia, thrombocytopenia, and anemia. Monitor blood counts regularly.
Serious Infections & Sepsis: Patients may be at increased risk. Promptly evaluate and treat signs of infection.
Drug Interactions: Concomitant use with strong CYP3A inhibitors should be avoided unless necessary.
Pregnancy Risk: May cause fetal harm. Use effective contraception during and for some time after treatment.
To access VANFLYTA (Quizartinib) legally in India via Global Rare Meds, the following are required:
Required Documents:
- Valid prescription from a licensed oncologist or hematologist
- Supporting diagnostic reports (confirming FLT3-ITD mutation and AML diagnosis)
- Government-issued ID of the patient
- Import permit, if applicable
Availability:
VANFLYTA is not commercially available in Indian retail pharmacies. Global Rare Meds supports named-patient import to cities such as Mumbai, Delhi, Hyderabad, Chennai, Kolkata, Bengaluru, Pune, and others.
📧 Email: info@globalraremeds.com
📞 Call / WhatsApp: +91-99675 15602
Global Rare Meds provides sourcing and delivery support for VANFLYTA (Quizartinib):
- Sourced from authorized distributors in the USA, Canada, Europe, or Australia
- Prescription-verified and dispensed by licensed pharmacists
- Delivered securely via our fulfillment center in Ambernath, Thane District
- Available for pan-India and international dispatch under legal and regulatory guidelines
Q1: What is the generic name of VANFLYTA?
A: The generic name is Quizartinib Dihydrochloride.
Q2: Who manufactures VANFLYTA?
A: It is manufactured by Daiichi Sankyo, Inc.
Q3: Is VANFLYTA FDA-approved?
A: Yes, VANFLYTA received U.S. FDA approval on July 20, 2023, for newly diagnosed FLT3-ITD+ AML.
Q4: What dosage forms are available?
A: VANFLYTA is available as film-coated tablets in 17.7 mg and 26.5 mg strengths for oral use.
Q5: What are the common side effects of VANFLYTA?
A: Common side effects include diarrhea, nausea, vomiting, abdominal pain, mucositis, neutropenia, headache, upper respiratory tract infections, and sepsis.
Q6: What are the storage conditions for VANFLYTA?
A: Store at 20°C to 25°C (68°F to 77°F). Temperature excursions permitted between 15°C and 30°C (59°F to 86°F).
Q7: How do I order VANFLYTA in India?
A: Contact Global Rare Meds with a valid prescription and diagnostic documents. We will assist with the import process and provide pricing and delivery timelines.
Q8: Is it safe to purchase VANFLYTA online in India?
A: Yes, Global Rare Meds provides legally compliant access to VANFLYTA for Indian patients through verified international sourcing.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
